<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1728-8800-2022-3176</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-3176</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Эпидемиология и профилактика</subject></subj-group></article-categories><title-group><article-title>Атерогенный индекс плазмы как дополнительный маркер неблагоприятных сердечно-сосудистых исходов</article-title><trans-title-group xml:lang="en"><trans-title>Atherogenic index of plasma as an additional marker of adverse cardiovascular outcomes</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4621-1618</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гринштейн</surname><given-names>Ю. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Grinshtein</surname><given-names>Yu. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Юрий Исаевич Гринштейн — доктор медицинских наук, профессор, заведующий кафедрой терапии ИПО.</p><p>Красноярск</p></bio><bio xml:lang="en"><p>Krasnoyarsk</p></bio><email xlink:type="simple">grinst.yi@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8002-2362</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шабалин</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shabalin</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Владимир Викторович Шабалин — кандидат медицинских наук, доцент кафедры терапии ИПО.</p><p>Красноярск, Тел.: +7 (913) 567-91-58</p></bio><bio xml:lang="en"><p>Krasnoyarsk</p></bio><email xlink:type="simple">vlshabalin@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1753-6816</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Руф</surname><given-names>Р. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Ruf</surname><given-names>R. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Руслан Райнгольдович Руф — кандидат медицинских наук, ассистент кафедры терапии ИПО.</p><p>Красноярск</p></bio><bio xml:lang="en"><p>Krasnoyarsk</p></bio><email xlink:type="simple">kromsolog@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2087-6483</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шальнова</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Shalnova</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Светлана Анатольевна Шальнова — доктор медицинских наук, профессор, руководитель отдела эпидемиологии хронических неинфекционных заболеваний.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">svetlanashalnova@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4453-8430</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Драпкина</surname><given-names>О. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Drapkina</surname><given-names>O. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Оксана Михайловна Драпкина — доктор медицинских наук, профессор, член-корр. РАН, директор.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">drapkina@bk.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО Красноярский государственный медицинский университет им. проф. В.Ф. Войно-Ясенецкого Минздрава России</institution></aff><aff xml:lang="en"><institution>V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУ Национальный медицинский исследовательский центр терапии и профилактической медицины Минздрава  России</institution></aff><aff xml:lang="en"><institution>National Medical Research Center for Therapy and Preventive Medicine</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>04</day><month>06</month><year>2022</year></pub-date><volume>21</volume><issue>5</issue><fpage>3176</fpage><lpage>3176</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Гринштейн Ю.И., Шабалин В.В., Руф Р.Р., Шальнова С.А., Драпкина О.М., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Гринштейн Ю.И., Шабалин В.В., Руф Р.Р., Шальнова С.А., Драпкина О.М.</copyright-holder><copyright-holder xml:lang="en">Grinshtein Y.I., Shabalin V.V., Ruf R.R., Shalnova S.A., Drapkina O.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/3176">https://cardiovascular.elpub.ru/jour/article/view/3176</self-uri><abstract><sec><title>Цель</title><p>Цель. На репрезентативной выборке населения Красноярского края оценить распределение атерогенного индекса плазмы (АИП), вычисляемого как десятичный логарифм отношения уровня триглицеридов к уровню холестерина (ХС) липопротеинов высокой плотности, и выявить возможные ассоциации между показателями АИП, различными сердечно-сосудистыми заболеваниями и метаболическими параметрами.</p></sec><sec><title>Материал и  методы</title><p>Материал и  методы. Проанализированы данные обследования случайной репрезентативной выборки из 1603 жителей города Красноярска и Березовского сельского района в возрасте 25-64 лет в рамках общероссийского эпидемиологического исследования ЭССЕ-РФ (Эпидемиология сердечно-сосудистых заболеваний и их факторов риска в регионах Российской Федерации). Статистическая обработка полученных данных выполнена в программах IBM SPSS v22 и Microsoft Excel 2021. Вычислена распространенность (в % от всех членов выборки или группы с 95% доверительными интервалами) артериальной гипертонии (АГ), ишемической болезни сердца, инфаркта миокарда (ИМ), инсульта и нарушения функции почек в целом по выборке и в группах с различным риском по значению АИП. Различия между группами проверялись по критерию χ2 с поправкой Йетса и считались значимыми при p≤0,05.</p></sec><sec><title>Результаты</title><p>Результаты. В зависимости от значения АИП 73,5% членов выборки оказались в группе низкого риска (АИП &lt;0,10), 10,4% отнесены к среднему риску (АИП в диапазоне 0,10-0,24) и 16,1% − к высокому (АИП &gt;0,24). Распространенность перенесенного ИМ или инсульта в группе среднего и высокого риска по АИП оказалась значимо выше, чем в группе низкого риска (р=0,024). Зарегистрировано закономерное увеличение распространенности АГ от 42,6% в группе низкого риска до 71,4% в группе высокого риска по АИП (p&lt;0,001 во всех случаях). Выявлено значимое увеличение доли пациентов с комбинацией АГ + повышенный уровень ХС липопротеинов низкой плотности по мере увеличения степени риска по АИП — с 28,4% при низком риске до 45,2% при высоком. Не обнаружено значимых различий между группами риска по АИП в распространенности ишемической болезни сердца и нарушений функции почек.</p></sec><sec><title>Заключение</title><p>Заключение. АИП является простым дополнительным расчетным лабораторным показателем, характеризующим атерогенные свойства плазмы. На материале когорты обследуемых в Красноярском крае повышенный уровень АИП ассоциируется с повышенной распространенностью ИМ и инсультов. Определение АИП может быть особенно полезным в случае нормальных исходных показателей ХС липопротеинов низкой плотности.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. Using a representative sample of the Krasnoyarsk Krai population, to evaluate the distribution of the atherogenic index of plasma (AIP), logarithmically transformed ratio of molar concentrations of triglycerides to high-density lipoprotein-cholesterol, and to identify  possible associations between AIP, various cardiovascular diseases, and metabolic parameters.</p></sec><sec><title>Material and methods</title><p>Material and methods. The study included a random representative sample of 1603 residents of the Krasnoyarsk and Berezovsky rural district aged 25-64 years as part of the Epidemiology of Cardiovascular Diseases and their Risk Factors in Regions of Russian Federation (ESSE-RF) study. Statistical processing was performed using IBM SPSS v22 and Microsoft Excel 2021 programs. We assessed the prevalence of hypertension (HTN), coronary artery disease, myocardial infarction (MI), stroke and renal dysfunction in the whole sample and in groups with different risk depending on AIP. Differences between groups were tested by Yates’s chi-squared test and were considered significant at p≤0,05.</p></sec><sec><title>Results</title><p>Results. Depending on AIP value, 73,5% of participants were in the low-risk group (AIP &lt;0,10), 10,4% — in moderate risk group (AIP, 0,100,24) and 16,1% — in high-risk group (AIP&gt;0,24). The prevalence of prior MI or stroke in the moderate and high-risk group for AIP was significantly higher than in the low-risk group (p=0,024). A regular increase in HTN prevalence was registered from 42,6% in the lowrisk group to 71,4% in the high-risk group for AIP (p&lt;0,001 for all). There was a significant increase in the proportion of patients with a combination of HTN + elevated low-density lipoprotein cholesterol levels as AIP risk increased — from 28,4% at low risk to 45,2% at high risk. There were no significant differences between AIP risk groups in the prevalence of coronary artery disease and renal dysfunction.</p></sec><sec><title>Conclusion</title><p>Conclusion. AIP is a simple additional estimated parameter that characterizes the atherogenic properties of plasma. Based on a cohort of Krasnoyarsk Krai subjects, an elevated level of AIP is associated with an increased prevalence of MI and strokes. Determination of AIP may be especially useful in the case of normal baseline low-density lipoprotein cholesterol levels.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>артериальная гипертония</kwd><kwd>атерогенный индекс плазмы</kwd><kwd>дислипидемия</kwd><kwd>сердечно-сосудистые факторы риска</kwd><kwd>эпидемиология</kwd></kwd-group><kwd-group xml:lang="en"><kwd>hypertension</kwd><kwd>atherogenic index of plasma</kwd><kwd>dyslipidemia</kwd><kwd>cardiovascular risk factors</kwd><kwd>epidemiology</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Borén J, Chapman MJ, Krauss RM, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41(24):231330. doi:10.1093/eurheartj/ehz962.</mixed-citation><mixed-citation xml:lang="en">Borén J, Chapman MJ, Krauss RM, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41(24):231330. doi:10.1093/eurheartj/ehz962.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Carr SS, Hooper AJ, Sullivan DR, et al. Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment. Pathology. 2019;51(2):148-54. doi:10.1016/j.pathol.2018.11.006.</mixed-citation><mixed-citation xml:lang="en">Carr SS, Hooper AJ, Sullivan DR, et al. Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment. Pathology. 2019;51(2):148-54. doi:10.1016/j.pathol.2018.11.006.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Iannuzzo G, Tripaldella M, Mallardo V, et al. Lipoprotein(a) Where Do We Stand? From the Physiopathology to Innovative Terapy. Biomedicines. 2021;9(7):838. doi:10.3390/biomedicines9070838.</mixed-citation><mixed-citation xml:lang="en">Iannuzzo G, Tripaldella M, Mallardo V, et al. Lipoprotein(a) Where Do We Stand? From the Physiopathology to Innovative Terapy. Biomedicines. 2021;9(7):838. doi:10.3390/biomedicines9070838.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Fras Z, Jug B, Penson PE, et al. Challenges and Opportunities on Lipid Metabolism Disorders Diagnosis and Therapy: Novel Insights and Future Perspective. Metabolites. 2021;11(9):611. doi:10.3390/metabo11090611.</mixed-citation><mixed-citation xml:lang="en">Fras Z, Jug B, Penson PE, et al. Challenges and Opportunities on Lipid Metabolism Disorders Diagnosis and Therapy: Novel Insights and Future Perspective. Metabolites. 2021;11(9):611. doi:10.3390/metabo11090611.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Dobiasova M, Frohlich J. The plasma parameter log (TG/HDLC) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apo B-lipoprotein-depleted plasma (FER(HDL). Clin Biochem. 2001;34(7):583-8.</mixed-citation><mixed-citation xml:lang="en">Dobiasova M, Frohlich J. The plasma parameter log (TG/HDLC) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apo B-lipoprotein-depleted plasma (FER(HDL). Clin Biochem. 2001;34(7):583-8.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Wang L, Chen F, Xiaoqi C, et al. Atherogenic Index of Plasma Is an Independent Risk Factor for Coronary Artery Disease and a Higher SYNTAX Score. Angiology. 2021;72(2):181-6. doi:10.1177/0003319720949804.</mixed-citation><mixed-citation xml:lang="en">Wang L, Chen F, Xiaoqi C, et al. Atherogenic Index of Plasma Is an Independent Risk Factor for Coronary Artery Disease and a Higher SYNTAX Score. Angiology. 2021;72(2):181-6. doi:10.1177/0003319720949804.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Huang H, Yu X, Li L, et al. Atherogenic index of plasma is related to coronary atherosclerotic disease in elderly individuals: a crosssectional study. Lipids Health Dis. 2021;20(1):68. doi:10.1186/s12944-021-01496-8.</mixed-citation><mixed-citation xml:lang="en">Huang H, Yu X, Li L, et al. Atherogenic index of plasma is related to coronary atherosclerotic disease in elderly individuals: a crosssectional study. Lipids Health Dis. 2021;20(1):68. doi:10.1186/s12944-021-01496-8.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Won KB, Han D, Lee JH, et al. Atherogenic index of plasma and coronary artery calcification progression beyond traditional risk factors according to baseline coronary artery calcium score. Sci Rep. 2020;10(1):21324. doi:10.1038/s41598-020-78350-x.</mixed-citation><mixed-citation xml:lang="en">Won KB, Han D, Lee JH, et al. Atherogenic index of plasma and coronary artery calcification progression beyond traditional risk factors according to baseline coronary artery calcium score. Sci Rep. 2020;10(1):21324. doi:10.1038/s41598-020-78350-x.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Edwards MK, Blaha MJ, Loprinzi PD. Atherogenic Index of Plasma and Triglyceride/High-Density Lipoprotein Cholesterol Ratio Predict Mortality Risk Better Than Individual Cholesterol Risk Factors, Among an Older Adult Population. Mayo Clin Proc. 2017;92(4):680-1. doi:10.1016/j.mayocp.2016.12.018.</mixed-citation><mixed-citation xml:lang="en">Edwards MK, Blaha MJ, Loprinzi PD. Atherogenic Index of Plasma and Triglyceride/High-Density Lipoprotein Cholesterol Ratio Predict Mortality Risk Better Than Individual Cholesterol Risk Factors, Among an Older Adult Population. Mayo Clin Proc. 2017;92(4):680-1. doi:10.1016/j.mayocp.2016.12.018.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Garg R, Knox N, Prasad S, et al. The Atherogenic Index of Plasma is Independently Associated with Symptomatic Carotid Artery Stenosis. J Stroke Cerebrovasc Dis. 2020;29(12):105351. doi:10.1016/j.jstrokecerebrovasdis.2020.105351.</mixed-citation><mixed-citation xml:lang="en">Garg R, Knox N, Prasad S, et al. The Atherogenic Index of Plasma is Independently Associated with Symptomatic Carotid Artery Stenosis. J Stroke Cerebrovasc Dis. 2020;29(12):105351. doi:10.1016/j.jstrokecerebrovasdis.2020.105351.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu XW, Deng FY, Lei SF. Meta-analysis of Atherogenic Index of Plasma and other lipid parameters in relation to risk of type 2 diabetes mellitus. Prim Care Diabetes. 2015;9(1):60-7. doi:10.1016/j.pcd.2014.03.007.</mixed-citation><mixed-citation xml:lang="en">Zhu XW, Deng FY, Lei SF. Meta-analysis of Atherogenic Index of Plasma and other lipid parameters in relation to risk of type 2 diabetes mellitus. Prim Care Diabetes. 2015;9(1):60-7. doi:10.1016/j.pcd.2014.03.007.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Huang F, Wang L, Zhang Q, et al. Elevated atherogenic index and higher triglyceride increase risk of kidney function decline: a 7-year cohort study in Chinese adults. Ren Fail. 2021;43(1):32-9. doi:10.1080/0886022X.2020.1853569.</mixed-citation><mixed-citation xml:lang="en">Huang F, Wang L, Zhang Q, et al. Elevated atherogenic index and higher triglyceride increase risk of kidney function decline: a 7-year cohort study in Chinese adults. Ren Fail. 2021;43(1):32-9. doi:10.1080/0886022X.2020.1853569.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Бойцов С. А., Чазов Е. И., Шляхто Е. В., и др. Научно-организационный комитет проекта ЭССЕ-РФ. Эпидемиология сердечно-сосудистых заболеваний в различных регионах России (ЭССЕ-РФ). Обоснование и дизайн исследования. Профилактическая медицина. 2013;16(6):25-34. EDN: STUSXL.</mixed-citation><mixed-citation xml:lang="en">Boitsov SA, Chazov EI, Shlyakhto EV, et al. Scientific and Organizing Committee of the Russian Federation essay. Epidemiology of cardiovascular diseases in different regions of Russia (ESSE-RF). The rationale for and design of the study. Profilakticheskaya Meditsina. 2013;16(6):25-34. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Гринштейн Ю. И., Петрова М. М., Шабалин В. В. и др. Распространенность артериальной гипертензии в Красноярском крае по данным эпидемиологического исследования ЭССЕ-РФ. Артериальная гипертензия. 2016;22(6):551-9. doi:10.18705/1607-419X-2016-22-6-551-559.</mixed-citation><mixed-citation xml:lang="en">Grinshtein YuI, Petrova MM, Shabalin VV, et al. The prevalence of arterial hypertension in Krasnoyarsky territory: the data from the epidemiology study ESSE-RF. “Arterial’naya Gipertenziya” (“Arterial Hypertension”). 2016;22(6):551-9. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Cook DG, Shaper AG, MacFarlane PW. Using the WHO (Rose) angina questionnaire in cardiovascular epidemiology. Int J Epidemiol. 1989;18(3):607-13. doi:10.1093/ije/18.3.607.</mixed-citation><mixed-citation xml:lang="en">Cook DG, Shaper AG, MacFarlane PW. Using the WHO (Rose) angina questionnaire in cardiovascular epidemiology. Int J Epidemiol. 1989;18(3):607-13. doi:10.1093/ije/18.3.607.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Prineas RJ, Crow RS, Zhang ZM. The Minnesota code manual of electrocardiographic findings. Springer Science &amp; Business Media, 2009. 327 p.</mixed-citation><mixed-citation xml:lang="en">Prineas RJ, Crow RS, Zhang ZM. The Minnesota code manual of electrocardiographic findings. Springer Science &amp; Business Media, 2009. 327 p.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Dobiasova M. AIP — atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice. Vnitr Lec. 2006;52(1):64-71.</mixed-citation><mixed-citation xml:lang="en">Dobiasova M. AIP — atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice. Vnitr Lec. 2006;52(1):64-71.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Quispe R, Manalac RJ, Faridi KF, et al. Relationship of the triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio to the remainder of the lipid profile: The Very Large Database of Lipids-4 (VLDL-4) study. Atherosclerosis. 2015;242(1):243-50. doi:10.1016/j.atherosclerosis.2015.06.057.</mixed-citation><mixed-citation xml:lang="en">Quispe R, Manalac RJ, Faridi KF, et al. Relationship of the triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio to the remainder of the lipid profile: The Very Large Database of Lipids-4 (VLDL-4) study. Atherosclerosis. 2015;242(1):243-50. doi:10.1016/j.atherosclerosis.2015.06.057.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Ivanova EA, Myasoedova VA, Melnichenko AA, et al. Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases. Oxid Med Cell Longev. 2017;2017:1273042. doi:10.1155/2017/1273042.</mixed-citation><mixed-citation xml:lang="en">Ivanova EA, Myasoedova VA, Melnichenko AA, et al. Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases. Oxid Med Cell Longev. 2017;2017:1273042. doi:10.1155/2017/1273042.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Santos HO, Earnest CP, Tinsley GM, et al. Small dense lowdensity lipoprotein-cholesterol (sdLDL-C): Analysis, effects on cardiovascular endpoints and dietary strategies. Prog Cardiovasc Dis. 2020;63(4):503-9. doi:10.1016/j.pcad.2020.04.009.</mixed-citation><mixed-citation xml:lang="en">Santos HO, Earnest CP, Tinsley GM, et al. Small dense lowdensity lipoprotein-cholesterol (sdLDL-C): Analysis, effects on cardiovascular endpoints and dietary strategies. Prog Cardiovasc Dis. 2020;63(4):503-9. doi:10.1016/j.pcad.2020.04.009.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Balling M, Nordestgaard BG, Langsted A, et al. Small Dense Low-Density Lipoprotein Cholesterol Predicts Atherosclerotic Cardiovascular Disease in the Copenhagen General Population Study. J Am Coll Cardiol. 2020;75(22):2873-5. doi:10.1016/j.jacc.2020.03.072.</mixed-citation><mixed-citation xml:lang="en">Balling M, Nordestgaard BG, Langsted A, et al. Small Dense Low-Density Lipoprotein Cholesterol Predicts Atherosclerotic Cardiovascular Disease in the Copenhagen General Population Study. J Am Coll Cardiol. 2020;75(22):2873-5. doi:10.1016/j.jacc.2020.03.072.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Ikezaki H, Lim E, Cupples LA, et al. Small Dense Low-Density Lipoprotein Cholesterol Is the Most Atherogenic Lipoprotein Parameter in the Prospective Framingham Offspring Study. J Am Heart Assoc. 2021;10(5):e019140. doi:10.1161/JAHA.120.019140.</mixed-citation><mixed-citation xml:lang="en">Ikezaki H, Lim E, Cupples LA, et al. Small Dense Low-Density Lipoprotein Cholesterol Is the Most Atherogenic Lipoprotein Parameter in the Prospective Framingham Offspring Study. J Am Heart Assoc. 2021;10(5):e019140. doi:10.1161/JAHA.120.019140.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Liou L, Kaptoge S. Association of small, dense LDL-cholesterol concentration and lipoprotein particle characteristics with coronary heart disease: A systematic review and meta-analysis. PLoS One. 2020;15(11):e0241993. doi:10.1371/journal.pone.0241993.</mixed-citation><mixed-citation xml:lang="en">Liou L, Kaptoge S. Association of small, dense LDL-cholesterol concentration and lipoprotein particle characteristics with coronary heart disease: A systematic review and meta-analysis. PLoS One. 2020;15(11):e0241993. doi:10.1371/journal.pone.0241993.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Qi Y, Liu J, Wang W, et al. High sdLDL Cholesterol can be Used to Reclassify Individuals with Low Cardiovascular Risk for Early Intervention: Findings from the Chinese Multi-Provincial Cohort Study. J Atheroscler Thromb. 2020;27(7):695-710. doi:10.5551/jat.49841.</mixed-citation><mixed-citation xml:lang="en">Qi Y, Liu J, Wang W, et al. High sdLDL Cholesterol can be Used to Reclassify Individuals with Low Cardiovascular Risk for Early Intervention: Findings from the Chinese Multi-Provincial Cohort Study. J Atheroscler Thromb. 2020;27(7):695-710. doi:10.5551/jat.49841.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Kanonidou C. Small dense low-density lipoprotein: Analytical review. Clin Chim Acta. 2021;520:172-8. doi:10.1016/j.cca.2021.06.012.</mixed-citation><mixed-citation xml:lang="en">Kanonidou C. Small dense low-density lipoprotein: Analytical review. Clin Chim Acta. 2021;520:172-8. doi:10.1016/j.cca.2021.06.012.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Watts GF, Chan DC. Atherogenic Dyslipoproteinemia and Management of ASCVD: Will New Indices Untie the Gordian Knot? J Am Coll Cardiol. 2020;75(17):2136-9. doi:10.1016/j.jacc.2020.03.032.</mixed-citation><mixed-citation xml:lang="en">Watts GF, Chan DC. Atherogenic Dyslipoproteinemia and Management of ASCVD: Will New Indices Untie the Gordian Knot? J Am Coll Cardiol. 2020;75(17):2136-9. doi:10.1016/j.jacc.2020.03.032.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-37. doi:10.1093/eurheartj/ehab484.</mixed-citation><mixed-citation xml:lang="en">Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-37. doi:10.1093/eurheartj/ehab484.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
